Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
J Nucl Med. 2010 Apr;51(4):618-23. doi: 10.2967/jnumed.109.071449. Epub 2010 Mar 17.
In this study, vitamin C was administered at various times as a sour stimulant to thyroid cancer patients, and the effect on salivary absorbed dose of therapeutic radioiodine ((131)I) was investigated.
Patients with differentiated thyroid cancer who had been prepared for thyroid remnant ablation after total thyroidectomy were prospectively recruited and, using a random-number table, were divided into 4 groups. In the hypothyroid condition, the patients in groups A, B, C, and D began sucking vitamin C (100 mg every 4 h in the daytime over 6 d) at 1, 5, 13, and 25 h, respectively, after receiving 3.7 GBq of (131)I. Scintigraphic images of the head and neck were serially acquired after (131)I administration to assess biokinetics in the salivary glands. Calculation of salivary absorbed dose was based on the MIRD schema of the Society of Nuclear Medicine.
Seventy-two patients (18, 18, 19, and 17 patients from groups A, B, C, and D, respectively) were eligible for the analysis of salivary dosimetry. Differences in absorbed doses to the parotid salivary gland (0.18 +/- 0.11, 0.16 +/- 0.07, 0.16 +/- 0.09, and 0.16 +/- 0.12 mGy/MBq in groups A, B, C, and D, respectively; P = 0.37) and submandibular salivary gland (0.19 +/- 0.05, 0.17 +/- 0.05, 0.18 +/- 0.07, and 0.17 +/- 0.06 mGy/MBq, respectively; P = 0.28) were not statistically significant among groups. Salivary cumulated activities arising from the first 24 h after (131)I administration accounted for 86.08% +/- 7.89% (range, 75%-98%) of total cumulated activities. Differences in salivary absorbed dose during the first 24 h were not statistically significant among the 4 groups either (P = 0.32 and 0.24, respectively, for the parotid and submandibular salivary glands).
Salivary stimulation with vitamin C at any time after (131)I administration has only a limited effect on salivary absorbed dose in thyroid cancer patients.
本研究采用不同时间给予维生素 C 作为甲状腺癌患者的酸味刺激物，观察其对治疗性放射性碘（(131)I）唾液吸收剂量的影响。
前瞻性招募甲状腺癌患者，在甲状腺全切术后准备甲状腺残留组织消融治疗，使用随机数字表将患者分为 4 组。在甲状腺功能减退状态下，A、B、C 和 D 组患者分别在接受 3.7GBq(131)I 后 1、5、13 和 25 小时开始每 4 小时口服 100mg 维生素 C，持续 6 天。在给予(131)I 后，连续采集头颈部闪烁图像以评估唾液腺的生物动力学。根据核医学学会的 MIRD 方案计算唾液吸收剂量。
72 例患者（A、B、C 和 D 组分别为 18、18、19 和 17 例）符合唾液剂量分析条件。腮腺唾液腺（A、B、C 和 D 组分别为 0.18±0.11、0.16±0.07、0.16±0.09 和 0.16±0.12mGy/MBq；P=0.37）和颌下腺唾液腺（0.19±0.05、0.17±0.05、0.18±0.07 和 0.17±0.06mGy/MBq；P=0.28）吸收剂量差异无统计学意义。(131)I 治疗后 24 小时内的唾液累积活度占总累积活度的 86.08%±7.89%（范围为 75%-98%）。4 组间第 1 至 24 小时唾液吸收剂量差异无统计学意义（腮腺和颌下腺分别为 P=0.32 和 0.24）。
(131)I 治疗后任何时间给予维生素 C 刺激唾液分泌，对甲状腺癌患者的唾液吸收剂量仅有有限的影响。
Zotero 插件